
Extra Pneumococcal Dose Can Save Lives in Care Homes
An additional dose of a pneumococcal vaccine, either 23-valent pneumococcal polysaccharide vaccine (PPV23) or 20-valent pneumococcal conjugate vaccine (PCV20), for new care home residents upon entry could prevent a substantially higher proportion of invasive pneumococcal disease cases and deaths per dose than the single-dose schedule for 65-year-olds, with the PCV20 vaccine demonstrating greater effectiveness over the PPV23 vaccine.
METHODOLOGY:
Researchers in England conducted an observational surveillance study to evaluate the effect of administering an additional dose of a pneumococcal vaccine, either PPV23 or PCV20, at admission to new residents of older care homes, alongside the routine vaccination.
Using national invasive pneumococcal disease surveillance and other data sources, they analysed 121,587 new care home residents (83,271 women and 38,316 men) to estimate the potential number of invasive pneumococcal disease cases and deaths averted over 5 years and calculated the number needed to vaccinate (NNV) to prevent one vaccine-type case and one death.
They compared these results with those of 603,109 individuals (aged 65 years) from the general population who had received a single vaccine dose.
TAKEAWAY:
PPV23 immunisation of all new care home residents would prevent 36% of PPV23-type lifetime cases of invasive pneumococcal disease (NNV, 687) and 48% of deaths (NNV, 1095).
Similarly, PCV20 immunisation would prevent 75% of PCV20-type lifetime cases of invasive pneumococcal disease (NNV, 384) and 80% of deaths (NNV, 774).
An additional dose of both vaccines could prevent five times more cases and 18 times more deaths than the current immunisation policy for adults aged 65 years.
IN PRACTICE:
"Protecting older adults, especially those in aged care facilities, from infectious diseases is necessary to reduce morbidity and mortality. Vaccination, including against pneumococcus, is an effective strategy to promote healthy ageing," the author of a commentary wrote.
SOURCE:
This study was led by Fariyo Abdullahi, MSc, Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, England. It was published online on July 01, 2025, in The Lancet Healthy Longevity.
LIMITATIONS:
The national dataset could not identify individuals in temporary or respite care, potentially leading to an undercount of care home residents. This study relied on invasive pneumococcal disease risk estimates from the older study, which may not have reflected current conditions in England. The NNV might be underestimated as frail residents are less likely to receive invasive investigations.
DISCLOSURES:
The Immunisation and Vaccine Preventable Diseases Division provided vaccine manufacturers with postmarketing surveillance reports on pneumococcal and meningococcal infections, with cost recovery charges applied. One author reported performing contract research for pharmaceutical companies on behalf of St George's University of London and the UK Health Security Agency without personal remuneration. The other authors reported having no competing interests.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Hims & Hers Expands into Europe with ZAVA Acquisition
Hims & Hers Health Inc. (NYSE:HIMS) is one of the best NYSE stocks to buy for long term investment. On June 3, Hims & Hers Health announced its agreement to acquire ZAVA, which is a leading European digital health platform. The acquisition will expand Hims & Hers' international presence. In the upcoming quarters, Hims & Hers plans to establish its own branded presence in European markets by using ZAVA's robust platform. ZAVA currently serves over 1.3 million active customers and conducted ~2.3 million consultations in 2024 across the UK, Germany, France, and Ireland. A nurse in a telehealth platform talking with a patient on video call for consultation. Hims & Hers intends to introduce a new dimension of personalized digital health in Europe and offer tailored care across dermatology, weight loss, sexual health, and mental health. The expansion will include access to British, German, and French healthcare providers who will deliver services in local languages to ensure a localized experience. While specific offerings and their rollout will be announced in the coming months, the deal is expected to commence by 2026. Hims & Hers Health Inc. (NYSE:HIMS) is a telehealth platform that connects consumers to licensed healthcare professionals in the US, the UK, and internationally. While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
AstraZeneca (LSE:AZN) Wins EU Approval For Imfinzi In Muscle-Invasive Bladder Cancer
AstraZeneca received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone. The company's stock saw a 2% increase last week, a move that aligns with the broader market rise of 2%. While the approval of Imfinzi stands as a substantial development in improving treatment options for muscle-invasive bladder cancer, broader market trends predominantly played a role in AstraZeneca's recent stock movement. Global concerns regarding tariffs and other economic factors influenced financial markets, but AstraZeneca's noteworthy progress in medical treatments remains an important background element to its recent returns. We've discovered 3 warning signs for AstraZeneca that you should be aware of before investing here. Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The recent EU approval of Imfinzi offers AstraZeneca a promising opportunity to bolster its product portfolio, particularly in muscle-invasive bladder cancer treatments. This development may lead to stronger revenue and earnings forecasts, aligning with AstraZeneca's ongoing expansion and efforts to heighten market influence. Over the past five years, the company's total return, including share price and dividends, was 35.43%, indicating resilience and potential growth. However, its one-year performance fell short compared to the UK Pharmaceuticals industry, which returned a negative 9.4%. This underperformance could signal pressures despite robust long-term gains. In context of current market dynamics, AstraZeneca's share price movements are 29.9% below the analyst consensus price target of £133.57, positioning the stock as potentially undervalued. This discount highlights investor hesitance amid external challenges such as tariff implications and regulatory shifts, yet it also represents a margin for growth should the company navigate these hurdles effectively. Additionally, AstraZeneca's anticipated revenue growth outside China points to sustained demand, potentially enhancing its earnings. The Imfinzi approval underscores AstraZeneca's capacity for regulatory success, promising revenue growth while improving its competitive standing in a critical market segment. Click to explore a detailed breakdown of our findings in AstraZeneca's financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:AZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
'Ask for the test,' grandfather battling cancer calls on men to seek help
ALWAY man, Gary Hastie-Davies wants to give all men a much-needed message that may save your life. Gary, 69, has prostate cancer and has lived with treatment for years and has been able to enjoy his life and retirement. However, it could all be so different. For Gary, it all started with a passing comment at the end of a routine doctor's appointment. Gary, who has now retired from his security job and moved to Pentwyn, Cardiff, explains he was about to leave his GP appointment when the young doctor asked: 'Is there anything else I can help you with?' Gary says he shook his head. But the doctor paused, looked up, and asked again: 'Are you sure?' Man died at scene following serious multi-vehicle crash on M4 near Newport Violent attack with fence post on Newport pub leaves staff shaken Gary says he remembers hesitating — then finally mentioning some issues with sexual function. That small admission led to a rectal exam, which found nothing unusual. But the doctor followed up with a prostate-specific antigen (PSA) blood test, just to be safe. That test revealed high levels of prostate-specific antigen. A biopsy followed. The result? Aggressive prostate cancer. Fifteen years on, Gary is still living with the disease. It has spread to his torso, but ongoing treatment has kept it in check. Thanks to radiotherapy, chemotherapy and hormone therapy, he has been able to enjoy his retirement — especially tending to the parsnips and carrots on his allotment. 'You'd never guess I've got something in me that's trying to kill me,' he said. 'Unless they find a cure, I know it'll eventually get me. But right now, I feel good.' Gary has never forgotten the doctor who asked the extra question — and persisted. 'He was just out of medical school. I haven't seen him since, and I don't know his name. But I'd give anything to say thank you and give him a cwtch. He saved my life.' Gary's diagnosis marked the start of a difficult chapter. He battled panic attacks, gained weight, and lost his confidence. 'At one point, I was 20 stone. I saw a photo of myself on holiday and thought, 'I've got to sort this out.'' Since then, he's lost four stone, and says the cancer no longer feels like it's winning. The 2 'otherworldly' beaches in South Wales named among the UK's best for 2025 Support from wife, Carol, his two children and three grandchildren, has kept Gary going. So too did Dr Jim Barber at Velindre, who has guided his care from the beginning. 'He's been with me every step of the way,' said Gary. Gary is now lending his voice to Prostate Cancer UK's campaign calling for PSA blood tests — not rectal exams — to be the first step in diagnosing prostate cancer. 'That blood test is what caught mine. The exam didn't find anything.' The British Association of Urological Surgeons recently backed the charity's call to move away from routine rectal exams, calling the method outdated and unreliable. One in eight men in the UK will develop prostate cancer. Those over 50 — or over 45 for Black men or anyone with a family history — can request a free PSA test from their GP, even without symptoms. Gary says: 'Don't be embarrassed. Ask for the test. I did — just in time.'